AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38803220
Drug: Bortezomib-based chemotherapy
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-based chemotherapy plus therapeutic plasmapheresis (TPP) with 4% human albumin solution
Trial: 38803628
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg with a targeted prescribing pathway
Trial: 38804514
Drug: Felzartamab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felzartamab (16 mg/kg)
Trial: 38804517
Drug: Plozasiran 10
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 10 mg (quarterly dose)
Trial: 38804517
Drug: Plozasiran 25
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 25 mg (quarterly dose)
Trial: 38804517
Drug: Plozasiran 50
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 50 mg (quarterly dose)
Trial: 38804517
Drug: Plozasiran 50
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 50 mg (half-yearly dose)
Trial: 38804782
Drug: CK0801 Treg
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK0801 Treg cell therapy
Trial: 38804790
Drug: Olgotrelvir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olgotrelvir 600 mg twice daily for 5 days
Trial: 38805199
Drug: Twice-daily meditation
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily meditation
Trial: 38805199
Drug: Once-daily meditation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily meditation
Trial: 38805216
Drug: Immediate-intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-intensive atorvastatin (80 mg daily on days 1-21; 40 mg daily on days 22-90)
Trial: 38805216
Drug: Delayed-intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-intensive statin (placebo for days 1-3, followed by atorvastatin 40 mg daily on days 4-21, and then atorvastatin 40 mg daily on days 22-90)
Trial: 38805216
Drug: Immediate-intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-intensive atorvastatin
Trial: 38805228
Drug: Vaginal natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal natural progesterone therapy
Trial: 38805242
Drug: SHR-1703 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 (20 mg)
Trial: 38805242
Drug: SHR-1703 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 (75 mg)
Trial: 38805242
Drug: SHR-1703 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 (150 mg)
Trial: 38805242
Drug: SHR-1703 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 (300 mg)
Trial: 38805242
Drug: SHR-1703 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 (400 mg)
Trial: 38806045
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine TAK-003 (high-dose formulation)
Trial: 38806045
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine TAK-003 (standard approved formulation)
Trial: 38806430
Drug: Bronchoscopic thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchoscopic thermal vapour ablation (BTVA) treatment with the InterVapor system together with standard medical management
Trial: 38806430
Drug: BTVA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTVA treatment
Trial: 38806504
Drug: NOX-A12 (200/400/600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOX-A12 (200/400/600 mg per week)
Trial: 38806504
Drug: NOX-A12 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOX-A12 (600 mg per week)
Trial: 38806504
Drug: NOX-A12 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOX-A12 (various doses)
Trial: 38806700
Drug: BI 1467335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1467335 10 mg once daily for 12 weeks
Trial: 38806873
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam injection via needle-free auto-injector ZENEO (10 mg)
Trial: 38806873
Drug: Conventional syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional syringe midazolam injection (10 mg)
Trial: 38807116
Drug: VR-based simulation
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-based simulation training on geriatric oral health care (implemented twice at two weeks apart)
Trial: 38807146
Drug: TG103 (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 (15.0 mg)
Trial: 38807146
Drug: TG103 (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 (22.5 mg)
Trial: 38807146
Drug: TG103 (30.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 (30.0 mg)
Trial: 38807165
Drug: Interaction-focused music
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction-focused music therapy with cancer-affected children and their significant others (INMUT-KB)
Trial: 38807165
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy only with the child (MUT-K)
Trial: 38807183
Drug: Social memory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Social memory task administered in presence-only context
Trial: 38807183
Drug: Social memory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Social memory task administered in observation context
Trial: 38807948
Drug: Insertable cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertable cardiac monitor (ICM) in addition to standard post-MI treatment
Trial: 38807948
Drug: Standard post-MI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post-MI treatment without ICM
Trial: 38808319
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride 1000mg extended release once daily for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Trial: 38808319
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Trial: 38808361
Drug: SCG101 T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCG101 T-cell therapy
Trial: 38808476
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (3 mg escalating to 14 mg)
Trial: 38808490
Drug: Esketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.2 mg/kg infused intravenously over 40 minutes after childbirth)
Trial: 38809174
Drug: Zodasiran 50
RxNorm normalized name: Zodasiran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zodasiran 50 mg
Trial: 38809174
Drug: Zodasiran 100
RxNorm normalized name: Zodasiran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zodasiran 100 mg
Trial: 38809174
Drug: Zodasiran 200
RxNorm normalized name: Zodasiran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zodasiran 200 mg
Trial: 38809849
Drug: Benfotiamine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (600 mg or 1200 mg)
Trial: 38809849
Drug: Benfotiamine (selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (selected dose from phase 2A)
Trial: 38810172
Drug: Fetal antiseizure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal antiseizure medication (ASM) exposure
Trial: 38810600
Drug: Eculizumab (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (weekly induction of 600 mg or 900 mg followed by maintenance doses of 300 to 1200 mg every two weeks for up to 26 weeks)
Trial: 38810968
Drug: Modified NHL-BFM-95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified NHL-BFM-95 protocol combined with anaplastic lymphoma kinase inhibitor
Trial: 38810968
Drug: Anaplastic lymphoma
RxNorm normalized name: Anaplastic lymphoma kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaplastic lymphoma kinase inhibitor maintenance therapy
Trial: 38811045
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (iTRE) up to 12 breaths (72 µg) 4 times daily
Trial: 38811502
Drug: Esophageal self-dilation
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal self-dilation therapy (ESDT)
Trial: 38811554
Drug: Combination bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination bevacizumab (BVZ) therapy
Trial: 38811871
Drug: MAXPOWER Biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAXPOWER Biological Antibacterial Liquid
Trial: 38811911
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 2.5 mg/ml ropivacaine
Trial: 38811998
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor based treatment (empagliflozin and linagliptin)
Trial: 38811998
Drug: Non-SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-SGLT2 inhibitor based treatment (metformin and insulin)
Trial: 38812507
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with two doses of CoronaVac, 2 to 8 weeks post-infection
Trial: 38812507
Drug: SARS-CoV-2 infection
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine
Trial: 38813112
Drug: Fexagratinib 80
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fexagratinib 80 mg bd on a continuous schedule until disease progression or unacceptable toxicity
Trial: 38813388
Drug: EDP1815 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 (1 capsule daily)
Trial: 38813388
Drug: EDP1815 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 (4 capsules daily)
Trial: 38813388
Drug: EDP1815 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 (10 capsules daily)
Trial: 38813446
Drug: Vosoritide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosoritide (15 μg/kg/day, daily subcutaneous injection)
Trial: 38813444
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (blueberry juice and extract, tryptophan 2 g, tyrosine 10 g)
Trial: 38813551
Drug: R21/Matrix-M™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R21/Matrix-M™ vaccine at varied doses (10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™, 5µgR21/50µg Matrix-M™)
Trial: 38813551
Drug: R21/Matrix-M™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R21/Matrix-M™ vaccine
Trial: 38813815
Drug: ML GSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML GSP model based on clinical and CT image features
Trial: 38813838
Drug: onabotulinumtoxinA (onabotA)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: onabotulinumtoxinA (onabotA) treatment
Trial: 38814000
Drug: Acute bronchodilation
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute bronchodilation treatment, specific details not available.
Trial: 38814343
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum histidine concentration
Trial: 38814343
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum glutamate concentration
Trial: 38814343
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum phenylalanine concentration
Trial: 38814343
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum tyrosine concentration
Trial: 38814343
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum valine concentration
Trial: 38815151
Drug: Olaparib, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib, starting dose of 135 mg/m2/dose, administered twice daily for 28-day cycles.
Trial: 38815173
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU) four times daily for 8 weeks
Trial: 38815230
Drug: Ordering of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordering of recommended medication by providers
Trial: 38832837
Drug: Propofol infusions
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusions
Trial: 38816482
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 300 mg per day
Trial: 38816482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EA and CBZ
Trial: 38816821
Drug: Biological age
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological age determination by DNA methylation profile
Trial: 38816821
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors
Trial: 38816826
Drug: Personalized, risk-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized, risk-adapted therapy
Trial: 38818887
Drug: Fezolinetant 30
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 30 mg once daily for 52 weeks
Trial: 38818888
Drug: Fezolinetant 30
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 30 mg/day
Trial: 38818934
Drug: Ongericimab 150
RxNorm normalized name: Ongericimab
DrugBank: Ongericimab (DB18949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongericimab 150 mg every 2 weeks
Trial: 38818934
Drug: Ongericimab 300
RxNorm normalized name: Ongericimab
DrugBank: Ongericimab (DB18949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongericimab 300 mg every 4 weeks
Trial: 38819408
Drug: IP nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP nivolumab (0.5, 1, or 3 mg/kg)
Trial: 38819658
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg sebetralstat
Trial: 38819658
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg sebetralstat
Trial: 38819917
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (PediaFlù) plus standard of care (SoC)
Trial: 38820078
Drug: Asciminib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib (80 mg once daily)
Trial: 38820246
Drug: Community-wide universal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide universal HIV testing with treatment following national guidelines and TB screening (Arm B)
Trial: 38820422
Drug: Luspatercept (1.0-1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (1.0-1.75 mg/kg, 21-day cycles)
Trial: 38820549
Drug: ivonescimab plus
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivonescimab plus chemotherapy
Trial: 38820586
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioral Therapy (ICBT) with text messaging adjunct
Trial: 38820857
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) administered before exercise
Trial: 38820857
Drug: No methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No methylphenidate (MP) administered (without MP)
Trial: 38821545
Drug: 'My Bowels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'My Bowels on Track' smartphone application with weekly/biweekly electronic patient-reported outcomes (PROs) and alerting system.
Trial: 38822300
Drug: Daily tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Trial: 38822324
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive stimulation using HappyNeuron PRESCO software App on tablets, with three 20-minute sessions (first supervised by a neuropsychologist).
Trial: 38822391
Drug: Guanfacine (sympatholytic),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (sympatholytic), 6 weeks treatment
Trial: 38822391
Drug: Hydrochlorothiazide (diuretic),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (diuretic), 6 weeks treatment
Trial: 38822389
Drug: Handheld fluorescence
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Handheld fluorescence imaging device with 5-aminolevulinic acid (5-ALA) administration
Trial: 38822943
Drug: IV CM-101
RxNorm normalized name: TRAMETES VERSICOLOR STRAIN CM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CM-101 2.5 mg/kg
Trial: 38822943
Drug: SC CM-101
RxNorm normalized name: TRAMETES VERSICOLOR STRAIN CM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC CM-101 5.0 mg/kg
Trial: 38822943
Drug: IV CM-101
RxNorm normalized name: TRAMETES VERSICOLOR STRAIN CM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CM-101 (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 mg/kg)
Trial: 38822948
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four laser treatments
Trial: 38823034
Drug: Cabozantinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (40 mg p.o. daily on days 1-21 of a 21-day cycle) and Pembrolizumab (200 mg i.v. on day 1)
Trial: 38823410
Drug: BL-B01D1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-B01D1 at 3·0 mg/kg on days 1 and 8 every 3 weeks
Trial: 38823410
Drug: BL-B01D1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-B01D1 at 6·0 mg/kg on day 1 every 3 weeks
Trial: 38824442
Drug: Stepped palliative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped palliative care (initial visit within 4 weeks, subsequent visits based on treatment changes or hospitalizations)
Trial: 38824658
Drug: molecularly matched
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: molecularly matched therapy
Trial: 38824836
Drug: Antibiotic-cement coated
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-cement coated plate
Trial: 38824872
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid injection (ISI)
Trial: 38824918
Drug: Hydroxyurea PK
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea PK dosing
Trial: 38824918
Drug: Hydroxyurea default
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea default dose
Trial: 38824941
Drug: sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab (200 mg intravenously once every 3 weeks for 12 cycles)
Trial: 38824941
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (gemcitabine and cisplatin induction chemotherapy followed by concurrent cisplatin radiotherapy)
Trial: 38825005
Drug: Papaverine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (80 mg intravenous)
Trial: 38825005
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline solution)